What is the primary reason for this 8-K filing?

This filing announces the termination of a material definitive agreement, specifically the joint venture agreement for BeiGene Biologics Co., Ltd. BeOne Medicines is consolidating full ownership by acquiring the remaining 5% stake and repaying a substantial shareholder loan.

How is the acquisition and loan repayment being financed?

The company has secured new financing facilities totaling approximately $198.32 million from China Minsheng Banking Corp., Ltd. (CMBC) and up to RMB500 million from an affiliate of Hillhouse Capital Advisors, Ltd. The CMBC loan is for one year, renewable for up to three years, and the Hillhouse loan includes a credit enhancement facility.

What are the implications of becoming a 100% owner of BeiGene Biologics?

Becoming the sole owner of BeiGene Biologics streamlines operations and decision-making for the commercial-scale biologics manufacturing facility in Guangzhou, China. It eliminates the need to manage a joint venture partner and its associated agreements.

When is this transaction expected to be completed?

The transaction, including the acquisition of the equity interest and termination of the joint venture agreement, is subject to approval by the local State Administration for Market Regulation. This approval is expected in the fourth quarter of 2020.

ONC/BEIGF 8-K: Material Agreements

Summary

BeOne Medicines Ltd. (ONC) is terminating its joint venture, BeiGene Biologics Co., Ltd. ("BeiGene Biologics"), by acquiring the 5% equity interest held by Guangzhou High-tech Zone Technology Holding Group Co., Ltd. ("GET") for approximately RMB195 million. Simultaneously, BeiGene Biologics will fully repay a RMB900 million shareholder loan from GET, totaling approximately RMB1.15 billion, inclusive of interest. This transaction will result in BeiGene HK, a wholly-owned subsidiary, holding 100% of BeiGene Biologics, pending regulatory approval expected in Q4 2020. To fund these obligations, the Company has secured new financing. This includes a $118.32 million acquisition facility and an $80 million working capital facility (collectively, the "CMBC Loan") from China Minsheng Banking Corp., Ltd., a one-year term loan renewable for up to three years. Additionally, a loan facility from Hillhouse Capital Advisors, Ltd. ("Hillhouse"), a significant shareholder, will provide up to RMB500 million, with RMB100 million for general corporate purposes and RMB400 million as a credit enhancement for the CMBC Loan. The aggregate interest rate for both new loan facilities is 5.75% per year.

Key Highlights

1BeOne Medicines is consolidating full ownership of its biologics manufacturing facility by acquiring the remaining 5% joint venture stake.
2The company is terminating its joint venture agreement with GET, effective upon regulatory approval.
3A significant shareholder loan from GET, plus accrued interest, totaling approximately RMB1.15 billion will be fully repaid.
4New financing of approximately $198.32 million has been secured from China Minsheng Banking Corp., Ltd. to fund the acquisition and loan repayment.
5An additional credit facility of up to RMB500 million has been secured from an affiliate of Hillhouse Capital Advisors, Ltd., a significant shareholder, to support the financing.
6The aggregate interest rate for the new CMBC and Hillhouse loans is 5.75% per year.
7Regulatory approval for the transaction is anticipated in the fourth quarter of 2020.

BeOne Medicines Ltd. 8-K Report, Agreement Terminated (Oct 2, 2020)

Summary

Key Highlights

Frequently Asked Questions